Paloma Partners’s vTv Therapeutics VTVT Stock Holding History

Paloma Partners’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-862	Closed	-$53K	–	1970
2018 Q2	$53K	Buy	+862	New	+$63.7K	﹤0.01%	1553

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's VTVT Position: Q3 2018 in Review

Paloma Partners sold out of vTv Therapeutics (VTVT) in Q3 2018, closing a stake of 862 shares — an estimated $53K sold.

Paloma Partners first reported a position in VTVT in Q2 2018 and held it in 1 quarter. The position peaked at $53K in Q2 2018. 19 funds tracked by Wall St. Rank hold VTVT as of Q3 2018.

Paloma Partners reported no remaining vTv Therapeutics position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 862 vTv Therapeutics shares in Q3 2018, an estimated $53K.
Paloma Partners first reported a position in vTv Therapeutics in Q2 2018 and held it in 1 quarter.
Paloma Partners's vTv Therapeutics position peaked at $53K in Q2 2018.
19 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.